A phase II study of FolateImmune (EC90 with GP1-0100 adjuvant followed by EC17) with low dose cytokines interleukin-2 (IL-2) and interferon-{alpha} (IFN-{alpha}) in patients with refractory or metastatic cancer

Richard A. Messmann,R. Amato,J. Hernandez-McClain,B. Conley,H. Rogers,J. Lu,Philip S. Low,S. Bever,D. Morgenstern

A phase II study of FolateImmune (EC90 with GP1-0100 adjuvant followed by EC17) with low dose cytokines interleukin-2 (IL-2) and interferon-{alpha} (IFN-{alpha}) in patients with refractory or metastatic cancer

2007

Richard A. Messmann
R. Amato
J. Hernandez-McClain
B. Conley
H. Rogers
J. Lu
Philip S. Low
S. Bever
D. Morgenstern

13516 Background: FolateImmune is a folate-receptor (FR)-targeted immunotherapy that induces an immune response against tumor cells by marking them with a folate-hapten conjugate. The conjugate is ...

Keywords:

Cancer
Adjuvant
Interleukin 2
Interferon
Cancer research
Alpha (ethology)
Medicine
Immunotherapy
Immune system
Refractory
Pathology
Phases of clinical research
Conjugate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations